Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark

Cavero‐Carbonell, Clara; Hansen, Anne Vinkel; Rabanque-Hernández, Ma José; Martos, Carmen; Garne, Ester

doi:10.1002/bdra.23621

Cited by 37 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The major sequela caused by congenital ZIKV infection is microcephaly, which is evidenced in humans and animal models (Tang et al, 2016;Cui et al, 2017), and pregnant women are the direct victims of the ZIKV infection of fetus, making it vitally important that the treatment for pregnant women infection by ZIKV should be very cautious. Luckily, montelukast is classified as category B in the FDA pregnancy category and has been successfully used for treatment of pregnant women with asthma (Bakhireva et al, 2007;Cavero-Carbonell et al, 2017). Animal studies showed no adverse effects on embryo and fetal development at oral doses up to 400 mg/kg/day in rats or up to 100 mg/kg/day in rabbits, as described in the product information of montelukast (trade name Singulair R ) produced by Merck Sharp & Dohme, Ltd. With the combination of the fact that montelukast blocked vertical transmission of ZIKV in pregnant mice and its safety profile for pregnant women, it is promising that montelukast could be used for treatment of pregnant women infected with ZIKV.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Chen

Wang

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

The association of Zika virus (ZIKV) infection and severe complications including neurological sequelae especially fetal microcephaly has aroused global attentions since its outbreak in 2015. Currently, there are no vaccines or therapeutic drugs clinically approved for treatments of ZIKV infection, however. And the drugs used for treating ZIKV in pregnant women require a higher safety profile. Here, we identified an anti-asthmatic drug, montelukast, which is of safety profile for pregnant women and exhibited antiviral efficacy against ZIKV infection in vitro and in vivo. And we showed that montelukast could disrupt the integrity of the virions to release the viral genomic RNA, hence irreversibly inhibiting viral infectivity. In consideration of the neuro-protective activity that montelukast possessed, which was previously reported, it is promising that montelukast could be used for patients with ZIKV infection, particularly for pregnant women.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Montelukast is the leukotriene receptor antagonists successfully developed for treatment of asthmatic patients (Bakhireva et al, 2007;Cavero-Carbonell et al, 2017). However, little is known about its potential mechanism of the antiviral activity against ZIKV, DENV, and YFV.…”

Section: Montelukast Blocked Infection At the Early Stage Of Virus LImentioning

confidence: 99%

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Chen

Wang

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…107,108 Registry data showed limb reduction defects with montelukast, leading to a change in the drug labeling by the FDA. 109 Zileuton is best avoided in pregnancy due to inadequate data. 110 Safety data for biologics are limited to registry data, with no human studies available.…”

Section: Vasoconstrictive Effect Is Concerning In Pregnancymentioning

confidence: 99%

Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation

Miller

Mehta

Clark-Bilodeau

et al. 2020

Chest

View full text Add to dashboard Cite

Sleep disturbances are common in pregnancy, and sleep disorders may worsen or present de novo in the course of gestation. Managing a pregnant patient is complicated by the risk of teratogenicity, pharmacokinetic changes, and the dynamic nature of pregnancy. Although nonpharmacologic interventions are likely safest, they are often ineffective, and a patient is left dealing with frustrations of the sleep disturbance, as well as the negative outcomes of poor sleep in pregnancy. As with any other condition in pregnancy, management requires an understanding of pregnancy physiology, knowledge of the impact of a given condition on pregnancy or fetal and neonatal outcomes, and an ability to weigh the risk of the exposure to an untreated, or poorly treated condition, against the risk of a given drug. In partnership with the pregnant patient or couple, options for therapy should be reviewed in the context of the impact of the condition on pregnancy and offspring outcomes, while understanding that data (positive or negative) on the impact of therapy on perinatal outcomes are lacking. This article reviews the epidemiology of sleep disorders in pregnancy, general principles of prescribing in pregnancy and lactation, and safety surrounding therapeutic options in pregnancy.CHEST 2020; 157(1): [184][185][186][187][188][189][190][191][192][193][194][195][196][197]

show abstract

“…Montelukast was associated with a similar safety profile to placebo and was well tolerated with minimal adverse effects. Montelukast is classified as pregnancy risk category B1; studies in asthma have indicated an increased risk in of preterm birth and maternal complications, but no increased risk of congenital anomalies …”

Section: Resultsmentioning

confidence: 99%

“…Montelukast is classified as pregnancy risk category B1; studies in asthma have indicated an increased risk in of preterm birth and maternal complications, but no increased risk of congenital anomalies. 51…”

Section: Leflunomidementioning

confidence: 99%

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Rademaker

Agnew

Andrews³

et al. 2019

Aust J Dermatology

View full text Add to dashboard Cite

With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real‐world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

show abstract

Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark

Cited by 37 publications

References 34 publications

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Contact Info

Product

Resources

About